Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
CheckMate 067
Description:
A clinical trial of nivolumab, ipilimumab, and their combination as immunotherapy for advanced melanoma.
Primary topic:
Cancer Immunotherapy and Biomarkers (70%)
Related topics:
Cancer Immunotherapy and Biomarkers (70%),
Health Systems, Economic Evaluations, Quality of Life (12%)
OpenAlex ID:
keywords/checkmate-067
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
2019
·
James Larkin
, Vanna Chiarion-Sileni
, et al.
·
New England Journal of Medicine
·
4,047
PDF
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
2018
·
Frank Stephen Hodi
, Vanna Chiarion-Sileni
, et al.
·
The Lancet Oncology
·
1,528
Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition
2020
·
Andressa S Laino
, David Woods
, et al.
·
Journal for ImmunoTherapy of Cancer
·
276
PDF
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials
2017
·
Georgina V. Long
, Jeffrey S. Weber
, et al.
·
JAMA Oncology
·
194
CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.
2021
·
Jedd D. Wolchok
, Vanna Chiarion-Sileni
, et al.
·
Journal of Clinical Oncology
·
169
Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.
2022
·
F. Stephen Hodi
, Vanna Chiarion -Sileni
, et al.
·
Journal of Clinical Oncology
·
93
CheckMate 067: Long-term outcomes in patients with mucosal melanoma.
2020
·
Alexander Noor Shoushtari
, John Wagstaff
, et al.
·
Journal of Clinical Oncology
·
87
Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition—A Pooled Analysis of Patients With Advanced Melanoma
2019
·
Meredith M. Regan
, Lillian Werner
, et al.
·
Journal of Clinical Oncology
·
87
Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States
2017
·
Anna Oh
, Dang M. Tran
, et al.
·
Journal of Managed Care & Specialty Pharmacy
·
86
PDF
Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).
2016
·
Jedd D. Wolchok
, Vanna Chiarion-Sileni
, et al.
·
Journal of Clinical Oncology
·
78
Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation
2017
·
Eddie Gibson
, Ian Koblbauer
, et al.
·
PharmacoEconomics
·
71
PDF
First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data
2024
·
Georgina V. Long
, Evan J. Lipson
, et al.
·
Journal of Clinical Oncology
·
70
PDF
Abstract CT075: Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma (CheckMate 067)
2017
·
James Larkin
, Vanna Chiarion-Sileni
, et al.
·
Cancer Research
·
63
Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition.
2019
·
Jeffrey S. Weber
, Hao Tang
, et al.
·
Journal of Clinical Oncology
·
51
Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).
2015
·
Jedd D. Wolchok
, Vanna Chiarion-Sileni
, et al.
·
Journal of Clinical Oncology
·
47
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067
2021
·
Meredith M Regan
, Charlene M Mantia
, et al.
·
Journal for ImmunoTherapy of Cancer
·
46
PDF
CheckMate-067: Raising the Bar for the Next Decade in Oncology
2021
·
Sarah A. Weiss
, Harriet Kluger
·
Journal of Clinical Oncology
·
35
Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial
2021
·
S. Branchoux
, C.L. Sofeu
, et al.
·
ESMO Open
·
33
PDF
Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma
2019
·
Edward J. Gibson
, Najida Begum
, et al.
·
Journal of Medical Economics
·
31
PDF
Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands
2023
·
Michiel C.T. van Zeijl
, Jesper van Breeschoten
, et al.
·
Journal of Immunotherapy
·
28
LAG3-PD1 or CTLA4-PD1 Inhibition in Advanced Melanoma: Indirect Cross Comparisons of the CheckMate-067 and RELATIVITY-047 Trials
2022
·
Run-Cong Nie
, Fei-Yang Zhang
, et al.
·
Cancers
·
24
PDF
5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma
2019
·
J.M.G. Larkin
, V. Chiarion-Sileni
, et al.
·
Annals of Oncology
·
24
PDF
CheckMate 067—frontline nivolumab improves PFS alone or in combination with ipilimumab
2015
·
Alessia Errico
·
Nature Reviews Clinical Oncology
·
23
Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma
2025
·
Kelsey R. Monson
, Robert Ferguson
, et al.
·
Nature Medicine
·
21
Impact of Extrapolation Model Choices on the Structural Uncertainty in Economic Evaluations for Cancer Immunotherapy: A Case Study of Checkmate 067
2023
·
Taihang Shao
, Mingye Zhao
, et al.
·
PharmacoEconomics - Open
·
21
PDF
Show more works
View as search
Works count:
116
Citation count:
7,537
Year
Topic
Type